Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)

Graves, Julia E.; Nunley, Kara S.; Heffernan, Michael

doi:10.1016/j.jaad.2006.07.019

Cited by 101 publications

(86 citation statements)

References 282 publications

(308 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As third-line therapies, biologicals targeting tumor necrosis factor-alpha (TNF-alpha) such as infliximab and adalimumab Q3 have been recently used in patients with neurosarcoidosis (124,125).…”

Section: Treatmentmentioning

confidence: 99%

Challenges in the diagnosis and treatment of neurosarcoidosis

et al. 2015

View full text Add to dashboard Cite

The diagnosis and treatment of neurosarcoidosis can be very challenging for several reasons. It affects clinically 5%-10% of sarcoidosis patients, but can be found in up to 25% of autopsies. These data reveal that a high percentage of asymptomatic or misdiagnosed cases can be missed at an initial diagnostic approach. Clinical and imaging findings are often non-specific since they can be found in a large number of neurological disorders. Histopathology can also be confounding if not performed by an expert pathologist and not placed in an appropriate clinical context. In this review, we discuss clinical features, laboratory findings, imaging, and histology of neurosarcoidosis, and we report current evidence regarding drug therapy. We conclude that a correct diagnostic approach should include a multidisciplinary evaluation involving clinicians, radiologists, and pathologists and that future studies should evaluate the genetic signature of neurosarcoidosis as they could be helpful in the assessment of this uncommon disease. With head-to-head comparisons of medical treatment for neurosarcoidosis still lacking due to the rarity of the disease and an increasing number of immunomodulating therapies at hand, novel therapeutic approaches are to be expected within the next few years. Key messages Neurosarcoidosis is a rare disorder that affects clinically 5%-10% of sarcoidosis patients, but can be found in up to 25% of autopsies, revealing that a high percentage of asymptomatic or misdiagnosed cases can be missed at an initial diagnostic approach. A multidisciplinary evaluation is useful to achieve a correct diagnosis because clinical and imaging findings are often non-specific. Corticosteroids are the first-line treatment for neurosarcoidosis, followed by steroid-sparing immune-modulating agents if prednisone therapy is insufficient. Dear Author, Please check these proofs carefully. It is the responsibility of the corresponding author to check against the original manuscript and approve or amend these proofs. A second proof is not normally provided. Informa Healthcare cannot be held responsible for uncorrected errors, even if introduced during the composition process. The journal reserves the right to charge for excessive author alterations, or for changes requested after the proofing stage has concluded.The following queries have arisen during the editing of your manuscript and are marked in the margins of the proofs. Unless advised otherwise, submit all corrections using the CATS online correction form. Once you have added all your corrections, please ensure you press the ''Submit All Corrections'' button.Please review the table of contributors below and confirm that the first and last names are structured correctly and that the authors are listed in the correct order of contribution. The diagnosis and treatment of neurosarcoidosis can be very challenging for several reasons. It affects clinically 5%-10% of sarcoidosis patients, but can be found in up to 25% of autopsies. These data reveal that a high percenta...

show abstract

Section: Treatmentmentioning

confidence: 99%

Challenges in the diagnosis and treatment of neurosarcoidosis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…1997 yılında CD20+ B hücreli lenfoma tedavisi için onay almıştır. CD20, B hücrelerine spesifik bir yüzey antijenidir, öncü B hücreleri ve gelişmiş B hücrelerin yüzeyinde eksprese olurken plazma hücreleri ve kök hücrelerin yüzeyinde eksprese olmaz 53 . Bu nedenle, rituksimab, plazma hücreleri ve prekürsör hematopoetik hücrelerde etkili olamaz.…”

Section: Azatiyoprinunclassified

Dermatolojik hastalıkların tedavisinde immunmodülasyon

Özgen¹,

Seçkin²

2013

TURKDERM

View full text Add to dashboard Cite

ÖzetDermatolojide kullanılan topikal ya da sistemik tedavilerin çok büyük bir kısmının, hatta fiziksel tedavi yöntemlerinin bile etki mekanizmaları arasında immünolojik etkiler önemli yer tutmaktadır. Bu etkiler, tedavi edilen hastalığa göre değişmek üzere, immun sistemin baskılanması ya da stimüle edilmesi veya mevcut fonksiyonların değiştirilmesi yönünde olabilir. Bu makalede, dermatolojik hastalıkların tedavisindeki etkilerini başlıca immunmodülasyon yoluyla gösteren ilaçlar anlatılmaktadır. Makalede yer alan tedavi seçenekleri azatiyoprin, mikofenolat mofetil, siklosporin, glukokortikosteroidler, topikal kalsinörin inhibitörleri, foto(kemo)terapi, intravenöz immunglobulin, interferon, rituksimab, omalizumab, imiquimod ve ekstrakorporeal fotoferez, özellikle immunmodülasyon yönündeki etkilerini vurgulayan bir bakış açısıyla anlatılmış, bu ajanların kullanım şekillerine, tedavi protokollerine, tedavi sırasında monitörizasyon konusundaki önemli noktalara yer verilmemiştir. Sum maryImmunological effects have an important role in the action mechanisms of the majority of topical and systemic agents, and even some physical treatment modalities in dermatology. Depending on the disease being treated, these effects may be suppression or stimulation of the immune system as well as modulation of the existing functions. Agents that show their effects mainly by immunmodulation in the treatment of dermatological diseases are discussed in the present article. Treatment alternatives included in the article, azathioprine, mycophenolate mofetil, cyclosporine, glucocorticosteroids, topical calcineurin inhibitors, photo(chemo)therapy, intravenous immunoglobuline, interferon, rituximab, omalizumab, imiquimod and extracorporeal photopheresis are discussed focusing especially on their immunomodulatory effects without any mention on their prescribing details, treatment protocols and monitorization aspects. (Turkderm 2013; 47 Girişİmmun sistem, dermatolojik hastalıkların pek çoğunun patogenezinde önemli rol oynamaktadır. Dermatolojide kullanılan tedaviler, hastalık patogenezinde ön planda yer alan immünolojik mekanizmaları hedef alarak etki gösterebilmektedir. Bu etki, tedavi edilen hastalığa göre değişmek üzere, immun sistemin baskılanması ya da stimüle edilmesi veya mevcut fonksiyonların değiştirilmesi yönünde olabilir. Aslında dermatolojide kullanılan topikal ya da sistemik tedavilerin çok büyük bir kısmının, hatta fiziksel tedavi yöntemlerinin bile etki mekanizmaları arasında immünolojik etkiler önemli yer tutmaktadır. Bu makalede, dermatolojik hastalıkların tedavisindeki etkilerini başlıca immunmodülasyon yoluyla gösteren ilaçlar anlatılmaktadır. Ancak, immunmodülasyon, değişen derecede, pek çok dermatolojik tedavi ajanı için geçerli bir etki mekanizması olduğundan, bu makale, bu tedavilerin tümünü kapsamamaktadır. Ayrıca makalede yer alan tedavi seçenekleri, özellikle immunmodülasyon yönündeki etkilerini vurgulayan bir bakış açısıyla anlatılmış, kullanım şekilleri, yan etkileri, monitörizasyon gibi konulara ayrıntılı yer veri...

show abstract

“…Several authors report on good therapeutic response to omalizumab (139)(140)(141)(142)(143)(144)(145)(146). Omalizumab is a steroid-sparing agent in autoimmune urticaria or CIU with angioedema (144).…”

Section: Omalizumabmentioning

confidence: 99%

Treatment of Chronic Urticaria

Tončić

Lipozenčić²,

Marinović³

2009

Urticaria and Angioedema, Second Edition

View full text Add to dashboard Cite

Summary Urticaria is a disorder characterized by rapid onset of localized swelling of the skin or mucosa, called wheals or urtica. According to frequency and duration, urticaria can be divided into acute and chronic type. Chronic urticaria is any type of urticaria occurring every day or twice per week, lasting longer than 6 weeks. Chronic urticaria is a common disorder and estimated prevalence is 1% of the population. Also, it is not rare in childhood. The pathogenesis of chronic urticaria has not yet been completely understood. Chronic urticaria is a heterogeneous group of disorders, and according to the etiology and cause, several groups of chronic urticaria are distinguished, i.e. autoimmune, pseudoallergic, infection-related, physical urticaria, vasculitis urticaria and idiopathic urticaria. Treatment and management of chronic urticaria can be non-pharmacological and pharmacological, and sometimes it is not possible to control the disease with antihistamines only, which are considered to be the mainstay of treatment. In severe cases of chronic urticaria, especially if autoimmunity has been proven, several authors describe different modules of immunomodulation: cyclosporine, cyclophosphamide, mycophenolate-mofetil, omalizumab, plasmapheresis, systemic corticosteroids, and immunoglobulin therapy. This article primarily addresses the treatment of chronic idiopathic and autoimmune urticaria.

show abstract

Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)

Cited by 101 publications

References 282 publications

Challenges in the diagnosis and treatment of neurosarcoidosis

Challenges in the diagnosis and treatment of neurosarcoidosis

Dermatolojik hastalıkların tedavisinde immunmodülasyon

Treatment of Chronic Urticaria

Contact Info

Product

Resources

About